THE BRITISH JOURNAL OF PSYCHIATRY

Volume 142

Published monthly

MARCH 1983

Founded in 1853 as the Asylum Journal and known as the Journal of Mental Science from 1855 to 1963.

EDITOR

J. L. Crammer

ASSOCIATE EDITORS

Martin Roth

Kenneth Rawnsley

ASSISTANT EDITORS

Sidney Crown John Cutting Gaius Davies Hugh Freeman Alan Kerr Margaret Little Julian Leff Andrew C. Smith

Philip Snaith William Spry Peter Tyrer Gregor Wilkinson

EDITORIAL MANAGEMENT Jacqueline Yates

ASSISTANT FOR THE BULLETIN
Alison Campbell

Correspondence, manuscripts, books for review, for both the *Journal* and the *Bulletin* should be addressed to the Editor, 17 Belgrave Square, London SW1X 8PG (Tel 01-235 8857). See inside front cover for further instructions.

Advertising enquiries, correspondence and copy should be addressed to Mr. Peter T. Mell, Advertisement Manager, PTM Professional Publications Ltd, 282 High Street, Sutton, Surrey SM1 1PQ (Tel 01-642 0162 PBX).

Subscriptions for non-members of the College are payable directly to the printers, Headley Brothers Ltd, to whom all queries about missing or faulty copies should be addressed within six months of publication and who also supply on order Special Publications and Gaskell Books.

Annual subscription rates 1983 (12 issues post free)

Inland: Institutions £65.00; Individuals £55.00

Overseas: Institutions £90.00, US\$200.00; Individuals £75.00, US\$165.00

Single copies of the Journal, £6.00, US\$12.00 (post free).

Bargain: Special American private subscription \$45.00 for 12 issues post free, to personal subscribers affirming the Journal is for their own use and naming the institution to which they belong and which already subscribes at the institutional rate. For residents of North America only.

USA Mailing Agents, Expediters of the Printed Word Ltd., 527 Madison Avenue, Suite 1217, New York, NY 10022. 2nd Class postage paid at New York City, NY. (USPS No. 536-870).

Back issues published in 1981 may be purchased from Headley Brothers Ltd and all previous issues from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent, England (Tel 0303 57421).

Printed by Headley Brothers Ltd, Ashford, Kent TN24 8HH, England (Tel 0233 23131).

© 1983 THE ROYAL COLLEGE OF PSYCHIATRISTS

Private Psychiatric Treatment

FOR ACUTE MENTAL DISORDERS

At St. Andrew's Hospital, Northampton, particular emphasis is placed on short-stay treatment of acute mental disorders. The highest standards of medical and nursing care are provided in a relaxed, understanding atmosphere.

The short-stay unit is part of St. Andrew's comprehensive facility for private psychiatric treatment. The hospital is set in 100 acres of parkland, with its own golf course, tennis and squash courts, indoor swimming pool and gymnasium.

Subscribers to private medical insurance schemes may be able to claim for treatment within the terms of their cover.

For further information, write—postage free—to the Medical Director, FREEPOST, Dept BJP3, St. Andrew's Hospital, Northampton, NN1 5DG. Telephone (0604) 21311.

St. Andrew's Hospital



BOWDEN HOUSE

For treatment of all forms and severity of psychiatric illness usually in the short term, including acute Psychosis, Alcoholism and Psycho-geriatric cases

- Medical and nursing care to a high standard provided in an informal and friendly atmosphere
- Special arrangements for patients covered by a private Medical Insurance scheme

For further information please contact the Medical Director

London Road, Harrow-on-the-Hill 01-864-0221

THIS IS A SPECIAL MESSAGE ADDRESSED TO THE MEDICAL PROFESSION AND TO WORKERS IN THE PROBATION AND SOCIAL SERVICES



THE RICHMOND FELLOWSHIP

provides a network of Therapeutic Communities throughout the United Kingdom offering a supportive environment to emotionally disturbed adults and young people as well as catering for developmentally handicapped children.

For information please write to:

The Admissions Officer, The Richmond Fellowship, 8 Addison Road, London W14 8DL, or telephone: 01-603 6373.

1959-1983: TWENTY-FOUR YEARS OF CARING

VICTORIA, AUSTRALIA HEALTH COMMISSION OF VICTORIA

MENTAL HEALTH DIVISION

PSYCHIATRIST/CONSULTANT PSYCHIATRIST

An experienced and able psychiatrist is sought who will be able to take an active part in the expansion and development of the Forensic Psychiatry Service which is currently under way. Units are at present operating in two central prisons with indirect responsibility for the smaller country prisons and there is an out-patient unit which it is proposed will be moved and enlarged in the near future. This unit will be concerned with employment, supervision and teaching of post-graduate psychiatric trainees as well as other post-graduate general practitioners.

The service as a whole is integrated with the alcohol and drug abuse treatment service and this is in the process of setting up a team of specialised staff who will assume responsibility for some of such problems in the correctional service but remain closely associated with the treatment, assessment and advisory service. The medical staff within the service are supported by psychologists and nursing staff.

QUALIFICATIONS:

To be a fellow or member of the Royal Australian and New Zealand College of Psychiatrists or to possess other recognised equivalent post-graduate qualifications in psychiatry and be eligible for registration as a legal qualified medical practitioner in the State of Victoria.

SALARY:

From \$36,442 to \$48,474 (commencing salary will be within the above range according to experience. Re-location assistance available).

Applications should include name, date and place of birth and nationality; address for communication and telephone number; details of medical education including special qualifications; details of previous employment, and names and addresses of three referees and should be forwarded to:

Recruitment Officer, Health Commission of Victoria, 555 Collins Street, MELBOURNE, VIC. 3000 AUSTRALIA.

ENQUIRIES TO:

DR. A. KESSELL,
Deputy Director,
Mental Health Division,
555 Collins Street,
MELBOURNE, VIC. 3000
AUSTRALIA

Tel. No: (03) 616 7977

ACADEMIC PRESS



THE INFLUENCE OF PORNOGRAPHY ON BEHAVIOUR

edited by Maurice Yaffe and Edward Nelson December 1982, xxi + 276pp., 0.12.767850.6 \$ 26.00 / £14.00 (UK only)

Does exposure to pornography lead to a change in morals and behaviour? This book assesses the evidence on both sides of the pornography argument, and supplements these with discussions on the problem of censorship, the use of explicit material in sex education and therapy, women's reactions to pornography, the difference between pornography and erotic art, the development of the law, and the use of psychologists as expert witnesses in obscenity trials. Finally, recommendations are made for changes in the law. The whole subject is put into historical and cross-cultural perspective and approached, wherever possible, from an empirical point of view.

PSYCHIATRY AND GENERAL PRACTICE

edited by Anthony W. Clare and Malcolm Lader September 1982, xvi + 166pp., 0.12.174720.4 £12.60 (UK only) / \$23.50

The book is an account of the proceedings of a unique conference at which representatives of the major disciplines involved in the provision of primary care in the United Kingdom and America met in 1981 to discuss research into the nature and extent of psychiatric health, the prospects for greater inter-disciplinary collaboration and the need for further research. It is the most up-to-date, concise and readable account of the identification, nature and management of psychiatric ill-health in primary care currently available.

PSYCHOTHERAPY: A COGNITIVE INTEGRATION OF THEORY AND PRACTICE

Anthony Ryle June 1982, viii + 196pp., 0.12.793710.2 \$ 22.00 / £11.80 (UK only)

Learning, emotion, symptoms, and neurotic difficulty are presented in terms of a new, simple, cognitive model, and the application of this model to individual psychotherapy involving the combined use of active and interpretive methods is described and illustrated. The book will be a valuable introduction for psychotherapy trainees, and a challenge to experienced workers whose thinking or practice is limited by their adherence to one or other of the rival schools.

MOTHERHOOD AND MENTAL ILLNESS

edited by I.F. Brockington and R. Kumar

August 1982, xi + 265pp., 0.12.790666.5 (Academic Press) 0.8089.1481.2 (Grune & Stratton) \$28.00 / £15.00 (UK only)

About half a million babies are born each year in England: two out of every three recently delivered mothers are likely to experience the maternity blues, one in tem may go on to become depressed post-natally and one or two in every thousand may need to be admitted to a mental hospital with a post-partum psychosis. This book is the first to review the whole field of mental illness in pregnancy and the puerperium in a comprehensive and critical way. Contributors discuss features in the social circumstances, in the biological and psychological events that occur during pregnancy and after delivery which may lead to puerperal psychiatric disorders. The consequences of such disorders and how they are best managed is considered in depth.

24-28 OVAL ROAD, LONDON, NW1 7DX 111 FIFTH AVENUE, NEW. YORK, NY 10003, USA

in anxiety in anxiety associated with depression

the benzodiazepine with a wide therapeutic range

- effective in relieving the somatic and psychic symptoms of both anxiety and anxiety associated with depression
 - excellent patient tolerance
 - low incidence of side effects



outbursts, excitement, and confusion. Other rare adverse effects including hypotension, gastrointestinal and visual disturbances, skin rashes, urinary retention, headache, vertigo, changes in libido, blood dyscrasias and jaundice have also been reported. Dependence Potential and Withdrawal Symptoms in general the dependence potential of benzodiazepines is low, but this increases when high dosage is attained, especially when given over long periods. This is particularly, so in patients with a history of alcoholism, drug abuse or in patients with an arked personality disorders. Regular monitoring of treatment in such patients is essential and routine repeat prescriptions should be avoided. Treatment in all patients should be withdrawn gradually as vymptoms vuch a depression, nervousness, rebound invomnia, irritability, sweating and diarrhoca have been reported following abrupt cessation of treatment in patients receiving even normal therapeutic dows for short periods of time. Abrupt withdrawal following excessive dosage may produce confusion, toxic


psychosis, convulsions or a condition resembling delirium tremens. Overdosage Manifestations of Xanax overdosage include extensions of its pharmacological activity, namely acaxia and somolence. Induced vomiting and/or gastric lavage are indicated. As in all cases of drug overdosage, respiration, pulse and blood pressure should be monitored and supported by general measures when necessary Intravenous fullish may be administered and an adequate airway maintained. Animal experiments have suggested that forced diuresis or haemodialysis are probably of little value in treating overdosage. As with the management of any overdosage, the physician should bear in mind that multiple agents may have been ingested. Pharmaceutical Prevautions Protect from light. Legal Category POM. Package Quantities Bottles of 100. Further laformation Aftrazolam is readily absorbed. Following oral administration, peak concentrations in the plasma occur after 1-2 hours. The mean half-life is 12-15 hours. Repeated dosage may lead to accumulation and this should be borne in mind in elderly

patients and those with impaired renal or hepatic function. Alprazolam and its metabolites are excreted primarily in the urine. Xanax did not affect the prothrombin times or plasma warfarin levels in male volunteers administered sodium warfarin orally. Product Lieence Numbers 0.25 mg tablet PL 0.032/0093, 8.95 mg tablet PL 0.032/0093. Besse NHS Cost 0.25 mg tablet 3.3 pence, 0.5 mg tablet 6.5 pence.

UPJOHN LIMITED CRAWLEY WEST SUSSEX

Registered Trademark: Xanax






Just one each morning

Prescribing Information Presentation Merital AM film-coated tablets contain 100mg nomifensine hydrogen maleate. Uses Antidepressant for use in depressive illness with or without accompanying anxiety. Dose and Administration Up to 100mg may be given as a single daily dose in the morning. Some patients, particularly the elderly, who are known to be sensitive to the effects of psychotropic drugs may need a lower dose. Normal dose range 75-200mg daily. At the present time there is insufficient experience of the use of Merital in children to enable any dosage recommendation to be made. Contra-indications, warnings etc. Use in pregnancy only if there are compelling reasons. Mental may antagonise the hypotensive effects of adrenergic neurone-blocking drugs and may potentiate therapeutic and adverse effects of levolopa and other dopamine agonists. Use with caution in patients with ischaemic heart disease. Do not use in conjunction with monoamine oxidase inhibitors. Adverse effects include sleep disturbance, restlessness, pulpitations, nausea, headache, dryness of the mouth and dizziness. Also available Merital 50 capsules containing 50mg nomifensine hydrogen maleate and Merital 25 containing 25mg nomifensine hydrogen maleate. Basic NHS Price. Merital AM Tablets). 0086/0053 (Merital 50 Capsules), 0086/0052 (Merital 25 Capsules). 0086/0053 (Merital 25 Capsules).

Further information available on request from: Albert Products, A division of Hoechst UK Limited, 50 Salisbury Road, Hounslow, Middlesex, TW4 6JH.






Depixol® Injection increases the chances of successfu rehabilitation by:-

- * providing effective control of first-rank symptoms
- * elevating mood, lifting any associated depression, and improving work performance
- * ensuring smooth plasma concentration curves so reducing the likelihood of extra pyramidal side-effects.

PIXOL



For patients who are "dose resistant" or for whom low-volume injections are desirable:

(cis(z)-flupenthixol decanoate 100 mg/ml)



Prescribing Information

Prescribing Information

Depixol-Conc. Injection contain cis(2) flupenthixol decanoate. 20 mg per ml and 100 mg per ml respectively, in thin vegetable oil Indications Psychoses especially schizophrenia, particularly where there are associated features of withdrawal, inertia or apathy Dosage and Administration. Adults By deep intramuscular injection. 1-2 ml every 2-4 weeks, to a maximum of 400 mg weekly Children. Not recommended for children Side-Effects Early (frequent) and late (tare) dyskinesias. Extrapyramidal effects sometimes require dose reduction or anti-Parkinson drug treatment Contra-indications Not recommended for overactive patients, or for those with Parkinsonism, severe arteriosclerosis, senile confusional, or advanced renal, hepatic or cardiovascular disease, intolerance to other neuroleptics, pregnancy Package Quantities Boxes of 10-2 mg (1 ml). 10 x 40 mg (2 ml), 10 x 10 mg (1 ml) ampoules, 10 x 20 mg and 10 x 40 mg syringes. 1 x 200 mg (10 ml) and 1 x 500 mg (6 ml) vials. Purther Information Overdosage should be treated (a) by anti-cholinergic anti-Parkinson drugs if extrapyramidal symptoms occur (b) by sedation (with benizodiazepines) in the unlikely event of agitation or excitement (c) by noradfernaline or angional symptoms occur (b) by sedation (with benizodiazepines) in the unlikely event of agitation or excitement (c) by noradfernaline or angional symptoms. The patient is shocked. Basic NHS Cost 10 x 20 mg amps £15 22, 10 x 40 mg amps £25 47, 10 x 100 mg amps £35 70.

10 x 20 mg syringes £16 18, 10 x 40 mg syringes £26 46, 200 mg (10 ml) vial £14 46, 500 mg (5 ml) vial £26 93. PL 0458 007 008, PA 115 (1 2.3.5.6).

Further information and data sheets available from: Lundbeck Limited, Lundbeck House, Hastings Street, Luton, Beds. LU1 5BE.